Option chain shows key data for Innovent Biologics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Innovent Biologics.

Innovent Biologics (OTC:IVBIY) Stock, Option Chain

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Biotech

News

Penny Stocks

Health Care

General

IVBIY

INNOVENT BIOLOGICS INC by Innovent Biologics Inc.

IVBXF

FDA Rejects Lilly&#39;s Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting

The FDA advisory committee voted against the full approval of Eli Lilly And Co&#39;s (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was conducted only in China and that its results did not apply to U.S. patients.

FDA AdComm Votes Against Lilly&#39;s Lung Cancer Drug, Sintilimab

Contracts

Innovent Biologics, UNION therapeutics Ink Licensing Pact For Inflammatory Dermatology Candidate

INNOVENT BIOLGCS UNSP/ADR by Innovent Biologics Inc.

Innovent Biologics Inc

Press Releases

Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer

Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease

Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

Earnings

Innovent Announces 2024 Annual Results and Business Updates

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting

Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

Innovent Biologics

Comments

Innovent Biologics

Innovent Biologics (IVBIY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga